RT Journal Article
SR Electronic
T1 The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JF International Society of Hair Restoration Surgery
FD Publication of the International Society of Hair Restoration Surgery
SP 153
OP 166
DO 10.33589/32.5.153
VO 32
IS 5
A1 Pannu, Sukhmani
A1 Ly, Nathalie
A1 Abidi, Zehara
A1 Fruechte, Sophia
A1 Farah, Ronda
A1 Arruda, Suleima
A1 Sadick, Neil
A1 Hordinsky, Maria
YR 2022
UL http://www.ISHRS-HTForum.org/content/32/5/153.abstract
AB Alopecia areata (AA), with a disease incidence of 2% in the USA, is the most common immune-mediated cause of hair loss in the world. There were no FDA approved treatments for AA in the past. All treatment modalities used alone or in combination with each other, were prescribed off label. The JAK inhibitor baricitinib was approved by the FDA in June 2022. While it’s a significant leap forward, we are still missing the safety profile data in multiple areas. Topical JAK inhibitors are being tested along with sublingual options including tofacitinib, ruxolitinib, and ritlecitinib. In this review, we discuss the JAK inhibitor baricitinib in detail, along with its dosing regimen, challenges presented in the clinic, missing data, and what the future may hold.